Clinical Trial Update: WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC [Phase 2]

View source ↗

Summary

Phase 2 window-of-opportunity trial evaluating combination therapy with Olaparib and Durvalumab in histologically proven epithelial ovarian cancer, currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: AGO Research GmbH | Conditions: Epithelial Ovarian Cancer | Phase 2 | Status: RECRUITING